Pharming Group NV
pharming.comWhat Do They Do?
Develops and sells treatments for rare immune and genetic diseases, including RUCONEST for acute hereditary angioedema and Joenja for APDS, to patients through healthcare providers and specialty pharmacies.
20-F for FY2025, filed Apr 2, 2026Pharming Group is a global biotechnology company that develops and commercializes innovative therapies for rare and ultra-rare diseases…View ↗
A) CommercialWe currently commercialize two approved therapies for distinct rare and ultra-rare disease areas.View ↗
RUCONEST®, our first approved product, is the first and only recombinant C1 esterase inhibitor, or rhC1-INH, protein replacement therapy…View ↗
Joenja® (leniolisib), our second marketed therapy, is an oral, selective phosphoinositide 3-kinase delta, or PI3Kδ, inhibitor approved in…View ↗
We currently commercialize Joenja® in the United States and the United Kingdom through our own sales and marketing infrastructure.View ↗
Who Are Their Customers?
The company sells through specialty pharmacies that distribute pharmaceuticals in its disease areas. For Joenja, it uses its own sales and marketing infrastructure in the United States and United Kingdom.
20-F for FY2025, filed Apr 2, 2026
20-F for FY2025, filed Apr 2, 2026
Two U.S. customers represented approximately $290.9 million, or 77%, of our net revenues in 2025, per customer $156.2 million and $134.7…View ↗
How Are They Changing?
Broader commercial portfolio
The older report described RUCONEST as its sole marketed product and Joenja as newly approved. The latest report describes two marketed therapies and adds napazimone to the pipeline following the acquisition of Abliva.
20-F for FY2022, filed Apr 5, 2023 20-F for FY2025, filed Apr 2, 2026A) CommercialWe currently commercialize two approved therapies for distinct rare and ultra-rare disease areas.View ↗
Joenja® (leniolisib), our second marketed therapy, is an oral, selective phosphoinositide 3-kinase delta, or PI3Kδ, inhibitor approved in…View ↗
c. Napazimone (KL1333) for primary mitochondrial diseaseIn 2025, our late-stage pipeline was strengthened through the acquisition of Abliva…View ↗
Who Do They Compete With?
Competes with BioCryst, BioMarin, CSL Behring, Intellia, Ionis, Kalvista, Pharvaris, and Takeda
20-F for FY2025, filed Apr 2, 2026We consider several companies to be our current and future competitors in the HAE space, including, but not limited to, BioCryst, BioMarin…View ↗
Loading...
